. Author manuscript; available in PMC: 2019 Jan 4.

Published in final edited form as: Expert Rev Ophthalmol. 2014 Jan 9;6(6):611–622. doi: 10.1586/eop.11.65

Table 2.

Overview of preclinical experiments and results for non-Rho kinase inhibitors that interact with the Rho GTPase pathway.

Non-ROCK inhibitors (target of inhibitor)	Results
ML-7 (myosin light chain kinase)	↓ TM contraction
	↓ MLC phosphorylation in TM cells
	↓ Scar in cell model
GGTI-DU40 (geranylgeranyl-transferase-1)	↑ Outflow
	↑ Cell separation and cell rounding in TM cells
	↓ Actin bundles and focal adhesions in TM cells
	↓ MLC phosphorylation in TM cells
	↓ Membrane localization of isoprenylated small GTPases and Gβγ in TM cells
Lovastatin, compactin (HMG-CoA reductase)	↑ Outflow
	↑ Cell rounding and actin depolymerization in CB and TM cells
	↓ Focal adhesions in CB and TM cells
	↓ MLC phosphorylation in TM and CB cells
	↓ Membrane-bound Rho GTPase in TM cells
	↓ Scar in cell model
Pyrrolopyrimidines (LIM kinase-2)	↓ IOP
Pyrrolopyrimidines (LIM kinase-2)	↑ Outflow
H-7 (serine/threonine kinases)	↓ IOP
	↑ Outflow
	↑ Alterations in cell shape, actin cytoskeleton and focal adhesion complexes in TM cells
	↑ Changes in morphology and contractility in SC and peri-SC cells

CB: Ciliary body; IOP: Intraocular pressure; MLC: Myosin light chain; ROCK: Rho kinase; SC: Schlemm’s canal; TM: Trabecular meshwork.